Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Net Margin (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Net Margin for 5 consecutive years, with 373.3% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Margin changed N/A year-over-year to 373.3%, compared with a TTM value of 439.76% through Sep 2025, up 211313.0%, and an annual FY2024 reading of 2180.45%, up 1009181.0% over the prior year.
  • Net Margin was 373.3% for Q3 2025 at Autolus Therapeutics, down from 229.02% in the prior quarter.
  • Across five years, Net Margin topped out at 2070.5% in Q1 2022 and bottomed at 138025.0% in Q4 2024.
  • Average Net Margin over 4 years is 19029.23%, with a median of 651.41% recorded in 2024.
  • The sharpest move saw Net Margin plummeted -515185bps in 2023, then surged 255966bps in 2024.
  • Year by year, Net Margin stood at 2070.5% in 2022, then plummeted by -645bps to 11292.86% in 2023, then tumbled by -1122bps to 138025.0% in 2024, then surged by 100bps to 373.3% in 2025.
  • Business Quant data shows Net Margin for AUTL at 373.3% in Q3 2025, 229.02% in Q2 2025, and 781.13% in Q1 2025.